^
Association details:
| Biomarker: | AKT3 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
3104 Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes
Published date:
11/04/2020
Excerpt:
This study included 12 high-risk MDS patients treated with AZA (75 mg/m2/day, days 1-5, sc) and LEN (10 mg/day, days 1-21, orally) every 4 weeks….This preliminary study shows that AZA+LEN therapy affects the expression of specific clusters of miRNAs that target the PI3K signalling and, more specifically, three inositide genes that are mutated and associated with loss of response to this combination therapy, i.e. PI3KCD, AKT3 and PLCG2.
Secondary therapy:
azacitidine
